These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of Vancomycin Area-Under-the-Curve Dosing Versus Trough Target-Based Dosing in Obese and Nonobese Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia. Covvey JR, Erickson O, Fiumara D, Mazzei K, Moszczenski Z, Slipak K, Nemecek BD, Zimmerman DE, Guarascio AJ. Ann Pharmacother; 2020 Jul; 54(7):644-651. PubMed ID: 31888350 [Abstract] [Full Text] [Related]
3. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Mogle BT, Steele JM, Seabury RW, Dang UJ, Kufel WD. Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357 [Abstract] [Full Text] [Related]
4. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia. Jung Y, Song KH, Cho Je, Kim HS, Kim NH, Kim TS, Choe PG, Chung JY, Park WB, Bang JH, Kim ES, Park KU, Park SW, Kim HB, Kim NJ, Oh MD. Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788 [Abstract] [Full Text] [Related]
5. Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Ghosh N, Chavada R, Maley M, van Hal SJ. Clin Microbiol Infect; 2014 Dec; 20(12):O1098-105. PubMed ID: 24890030 [Abstract] [Full Text] [Related]
6. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia. Song KH, Kim HB, Kim HS, Lee MJ, Jung Y, Kim G, Hwang JH, Kim NH, Kim M, Kim CJ, Choe PG, Chung JY, Park WB, Kim ES, Park KU, Kim NJ, Kim EC, Oh MD. Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059 [Abstract] [Full Text] [Related]
11. Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-analysis of Observational Studies. Prybylski JP. Pharmacotherapy; 2015 Oct 01; 35(10):889-98. PubMed ID: 26497475 [Abstract] [Full Text] [Related]
12. Implementation of vancomycin AUC/MIC dosing vs traditional trough dosing and incidence of acute kidney injury at a rural community hospital. McClure S, McElroy L, Gugkaeva Z. Am J Health Syst Pharm; 2024 May 24; 81(11):e283-e288. PubMed ID: 38253056 [Abstract] [Full Text] [Related]
13. Association between vancomycin trough concentration and area under the concentration-time curve in neonates. Frymoyer A, Hersh AL, El-Komy MH, Gaskari S, Su F, Drover DR, Van Meurs K. Antimicrob Agents Chemother; 2014 Nov 24; 58(11):6454-61. PubMed ID: 25136027 [Abstract] [Full Text] [Related]
17. Clinical outcomes of linezolid and vancomycin in patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus stratified by baseline renal function: a retrospective, cohort analysis. Liu P, Capitano B, Stein A, El-Solh AA. BMC Nephrol; 2017 May 22; 18(1):168. PubMed ID: 28532398 [Abstract] [Full Text] [Related]